Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gilead Sciences and Arcus Biosciences have updated their ongoing Phase 2 clinical study, titled ‘A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)’. The study aims to assess the safety and preliminary clinical activity of treatment combinations, with and without chemotherapy, in patients with advanced gastric, GEJ, and esophageal adenocarcinoma. This research is significant as it explores new therapeutic options for these challenging cancers.
The study is testing various combinations of drugs, including Domvanalimab, Zimberelimab, and Quemliclustat, alongside the chemotherapy regimen FOLFOX, which consists of oxaliplatin, leucovorin, and fluorouracil. These interventions aim to improve treatment outcomes for patients with advanced cancers.
The study is designed as a randomized, parallel assignment with no masking, focusing primarily on treatment. This straightforward design helps in evaluating the direct impact of the interventions on the participants.
Key dates for the study include its start on June 10, 2022, with an estimated completion date of June 26, 2025. These timelines are crucial for investors to track the progress and potential results of the study.
The update could influence the stock performance of Gilead Sciences and Arcus Biosciences, as positive outcomes may enhance investor confidence and market position. The study’s results could also impact the competitive landscape in the oncology sector, particularly for treatments targeting upper gastrointestinal tract malignancies.
The study is ongoing, with further details available on the ClinicalTrials portal.